This market is not running up or down on the Presidential election. If anything it is current monetary policy and easing.

Here is new information by CYDY

seekingalpha.com/.../...p...oval-of-leronlimab-for

Bank of America also gave a negative report on Tesla today.

I like everyone else is waiting for concrete verification of their drug by the FDA since there is so much questionable stuff being said from everyone. Of course, approval from other countries are welcome as well. Anyways, I don't see any compelling evidence against CYDY and what positive news comes out recently has been dashed. We're also still waiting for up-listing from this exchange which should help with the shorts who have been active.

Anyways, my suggestion especially for companies needing FDA approval is don't over extend yourself, be patient, and wait for the findings. Hopefully, we will be rewarded soon.

Health Care remain a positive feature of this market and should benefit on any recovery.

I was mistaken regarding Brazil. They are currently selling Elelyso, which was approved for Gaucher disease in Brazil which is growing their revenue in Brazil and is another income stream for them. This will not be affected if PRX-102 is approved or not.

Thanks.

There are other recombinant players listed below. I'm not aware one one targeting this exactly but you never know what comes down the pipeline.

Boehringer Ingelheim

Bristol-Myers Squibb

Celldex Therapeutics

Eli Liily

GlaxoSmithKline

Merck

Novartis

Regeneron Pharmaceuticals

Roche

Takeda

It's probably best to start by reading Wikipedia for a more complete definition. en....pedia.org/.../Beta_(finance).

The other players are listed in the article they are quite big and are conglomerates.